U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 59

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated February 7, 2017	4. Expiration Date: October 31, 2025
1. SSM Health St. Clare Hospital-Fenton 2. 1015 Bowles Ave. Fenton, MO 63026	3. License number: 24-11858-01 is amended in its entirety to read as follows:	5. Docket No.: 030-02368 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 2 curies total	C. For any use permitted by 10 CFR 35.300.
D. Iridium-192 permitted by 10 CFR 35.400	D. Sealed Sources (Best Medical International, Inc., Model 81-01)	D. 1 curie total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-11858-01	Docket or Reference Number 030-02368
	Amendment No. 59	

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed Sources (Bard Brachtherapy, Inc., Model STM 1251; Best Medical International, Inc., Model 2301 to 2316; Core Oncology, Inc., Model I-125 SL (ProstaSeed); Implant Sciences Corporation, Model 3500 (I-Plant); International Brachytherapy S.A., Model 1251L; IsoAid, LLC., Model IAI-125A (Advantage I-125); Medi-Physics, Inc., Model 6711 (OncoSeed); North American Scientific, Inc., Model MED3631; Syncor Pharmaceuticals, Inc., Model BT-125-1; Theragenics I-Seed, Model AgX100)	E. 1 curie total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed Sources (Best Medical International, Inc., Model 2331 and 2335; Core Ocology, Inc., Model I-125 SL; International Brachytherapy S.A., Model 1031L; IsoAid, LLC., Model IAPd-103A (Advantage Pd-103); Medi-Physics, Inc., Model 6733 (EchoSeed); North American Scientific, Inc., Model MED3633; Theragenics Corporation, Model TheraSeed 200)	F. 1 curie total	F. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-11858-01	Docket or Reference Number 030-02368
	Amendment No. 59	

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1015 Bowles Ave., Fenton, Missouri.

11. The Radiation Safety Officer (RSO) for this license is Wallace O. Fuhrman, CNMT.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)	Material and Use
Ronald Palmer, M.D.	10 CFR 35.100, 35.200, and 35.300
Andre Strzembosz, M.D.	10 CFR 35.100, 35.200, and 35.300
Karen J. Baranski, M.D.	10 CFR 35.100 and 35.200
Thomas P. Bocchini, M.D.	10 CFR 35.100 and 35.200
Robert J. Gresick, M.D.	10 CFR 35.100 and 35.200
Megan Maine Gau, M.D.	10 CFR 35.100 and 35.200
Robert Swanson, M.D.	10 CFR 35.300 and 35.400 (limited to Iodine-125 and Palladium-103)
John Bedwinek, M.D.	10 CFR 35.300 and 35.400
David Morris, M.D.	10 CFR 35.300 and 35.400
John Joseph Stephens, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)
Thomas M. Schroyer, M.D.	10 CFR 35.100 and 35.200
Rebecca J. Mueller, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)
Robert M. Fischer, M.D.	10 CFR 35.100 and 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-11858-01	Docket or Reference Number 030-02368
	Amendment No. 59	

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
    A. Application dated April 20, 2015 (ML15118A911)
    B. Letter dated September 29, 2015 (ML15273A058)
    C. Letter dated February 7, 2017 (ML17041A382)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: March 23, 2017

By: Sara A. Forster

Sara A. Forster
Region III